Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography
Ch. Kao et al., Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography, CLIN CANC R, 6(3), 2000, pp. 820-824
The purpose of this study was to retrospectively predict the chemotherapy r
esponse to paclitaxel in non-small cell lung cancer (NSCLC) using technetiu
m-99m methoxyisobutylisonitrile (Tc-99m MIBI) chest single-photon-emission
computed tomography (SPECT) to detect the expression of multidrug-resistanc
e-mediated M-r 170,000 P-glycoprotein, Before chemotherapy with Paclitaxel
(Taxol), 30 patients with stage IIIb or TV NSCLC were enrolled in this stud
y. Early chest SPECT 10 min after i.v. injection of Tc-99m MIBI was perform
ed to qualitatively interpret Tc-99m MIBI chest SPECT visually and quantita
tively calculate early tumor:normal lung ratios (T:NL) for quick assessment
of multidrug-resistant P-glycoprotein expression in NSCLC. On the basis of
qualitatively visual interpretation of early Tc-99m MIBI chest SPECT, all
of 15 (100%) cases with good response to chemotherapy with Taxol could be d
etected but 10 (67%) of 15 cases with poor response could not be detected.
Early Tc-99m MIBI chest SPECT could correctly predict chemotherapy response
in 25 (83%) of 30 of cases. The early T:NL were 3.30 +/- 0.82 for 15 patie
nts with good response and 2.02 +/- 0.19 for 5 patients with poor response.
The differences were significant (P < 0.05) by independent Student t tests
. However, no significant differences were found for other prognostic facto
rs (age, sex, tumor size, tumor location, stage, and cell type) between goo
d-response and poor-response patients. Early Tc-99m MIBI chest SPECT has th
e potential to predict chemotherapy response to Paclitaxel.